MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 130 filers reported holding MERSANA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,967 | +9.4% | 3,029,555 | +36.7% | 0.31% | -42.9% |
| Q1 2023 | $9,107 | -29.4% | 2,215,788 | +0.7% | 0.54% | -24.9% |
| Q4 2022 | $12,892 | -99.9% | 2,200,000 | 0.0% | 0.72% | +13.4% |
| Q3 2022 | $14,872,000 | +46.3% | 2,200,000 | 0.0% | 0.64% | +16.9% |
| Q2 2022 | $10,164,000 | +15.8% | 2,200,000 | 0.0% | 0.54% | +47.6% |
| Q1 2022 | $8,778,000 | +17.6% | 2,200,000 | +83.3% | 0.37% | +81.3% |
| Q4 2021 | $7,464,000 | -34.0% | 1,200,000 | 0.0% | 0.20% | -19.8% |
| Q3 2021 | $11,316,000 | -30.6% | 1,200,000 | 0.0% | 0.25% | -23.6% |
| Q2 2021 | $16,296,000 | -16.1% | 1,200,000 | 0.0% | 0.33% | -3.5% |
| Q1 2021 | $19,416,000 | -39.2% | 1,200,000 | 0.0% | 0.34% | -50.0% |
| Q4 2020 | $31,932,000 | +71.5% | 1,200,000 | +20.0% | 0.69% | +51.8% |
| Q3 2020 | $18,620,000 | -0.5% | 1,000,000 | +25.0% | 0.45% | -13.7% |
| Q2 2020 | $18,720,000 | – | 800,000 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 796,458 | $14,830,000 | 12.35% |
| Consonance Capital Management LP | 3,468,171 | $64,577,000 | 7.87% |
| Sarissa Capital Management LP | 2,837,000 | $52,824,000 | 6.22% |
| Bain Capital Life Sciences Investors, LLC | 3,445,667 | $64,158,000 | 5.98% |
| Ghost Tree Capital, LLC | 1,050,000 | $19,551,000 | 5.65% |
| NEA Management Company, LLC | 5,959,520 | $110,966,000 | 4.70% |
| Soleus Capital Management, L.P. | 393,041 | $7,318,000 | 3.88% |
| ACUTA CAPITAL PARTNERS, LLC | 667,500 | $12,429,000 | 3.38% |
| Avoro Capital Advisors LLC | 6,800,000 | $126,616,000 | 1.80% |
| FNY Investment Advisers, LLC | 199,800 | $3,720,000 | 1.57% |